Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter
1997

Paclitaxel for Bladder Cancer

Sample size: 14 publication Evidence: low

Author Information

Author(s): D Papamichael, CJ Gallagher, RTD Oliver, PW Johnson, J Waxman

Primary Institution: St Bartholomew's Hospital

Hypothesis

Can paclitaxel be effective in patients with previously treated locally advanced/metastatic transitional cell carcinoma of the bladder or ureter?

Conclusion

Paclitaxel showed low efficacy in treating relapsed patients with advanced bladder cancer, with only one patient responding.

Supporting Evidence

  • One patient achieved a partial response lasting 7.4 months.
  • Three patients experienced stable disease for 54-164 days.
  • Severe haematological toxicity was observed in 23 out of 42 treatment courses.

Takeaway

Doctors tested a medicine called paclitaxel on 14 patients with advanced bladder cancer, but it didn't work very well.

Methodology

Patients received paclitaxel at a dose of 200 mg/m² every 21 days, and their responses were assessed every two cycles.

Limitations

The study involved a small number of patients and focused on a group with poor prognosis.

Participant Demographics

Patients were aged 40-73, with a median age of 68, and included 9 males and 5 females.

Statistical Information

Confidence Interval

95% CI 2-12%

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication